Abnormal activity of transcription factors gli in high-grade gliomas

PLoS One. 2019 Feb 7;14(2):e0211980. doi: 10.1371/journal.pone.0211980. eCollection 2019.

Abstract

Malignant transformation is associated with loss of cell differentiation, anaplasia. Transcription factors gli, required for embryonic development, may be involved in this process. We studied the activity of transcription factors gli in high-grade gliomas and their role in maintenance of stem cell state and glioma cell survival. 20 glioma cell lines and a sample of a normal adult brain tissue were used in the present study. We found the expression of gli target genes, including GLI1 and FOXM1, in all tested glioma cell lines, but not in the normal tissue. Interestingly, the expression of gli target genes in some glioma cell lines was observed together with a high level of their transcriptional repressor, Gli3R. Knockdown of GLI3 in one of these lines resulted in decrease of gli target gene expression. These data suggest that Gli3R does not prevent the gli target genes transcription, and gli3 acts in glioma cells more as an activator, than a repressor of transcription. We observed that gli regulated the expression of such genes, as SOX2 or OCT4 that maintain stem cell state, and TET1, involving in DNA demethylation. Treatment with GANT61 or siRNA against GLI1, GLI2, or GLI3 could result in complete glioma cell death, while cyclopamine had a weaker and line-specific effect on glioma cell survival. Thus, the gli transcription factors are abnormally active in high-grade gliomas, regulate expression of genes, maintaining the stem cell state, and contribute to glioma cell survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Neoplasms / genetics*
  • Brain Neoplasms / metabolism
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Forkhead Box Protein M1 / genetics
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Knockdown Techniques
  • Glioma / genetics*
  • Glioma / metabolism
  • HeLa Cells
  • Humans
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / metabolism*
  • Nerve Tissue Proteins / antagonists & inhibitors
  • Nerve Tissue Proteins / genetics
  • Nuclear Proteins / antagonists & inhibitors
  • Nuclear Proteins / genetics
  • Pyridines / pharmacology*
  • Pyrimidines / pharmacology*
  • Repressor Proteins / antagonists & inhibitors
  • Repressor Proteins / genetics*
  • Zinc Finger Protein GLI1 / antagonists & inhibitors
  • Zinc Finger Protein GLI1 / genetics
  • Zinc Finger Protein Gli2 / antagonists & inhibitors
  • Zinc Finger Protein Gli2 / genetics
  • Zinc Finger Protein Gli3 / antagonists & inhibitors
  • Zinc Finger Protein Gli3 / genetics

Substances

  • FOXM1 protein, human
  • Forkhead Box Protein M1
  • GANT 61
  • GLI1 protein, human
  • GLI2 protein, human
  • GLI3 protein, human
  • Nerve Tissue Proteins
  • Nuclear Proteins
  • Pyridines
  • Pyrimidines
  • Repressor Proteins
  • Zinc Finger Protein GLI1
  • Zinc Finger Protein Gli2
  • Zinc Finger Protein Gli3

Grants and funding

This work was performed with financial assistance of UMNIK program of Russian Foundation for Assistance to Small Innovative Enterprises (FASIE) to Andrey V Volnitskiy, contract 16907, "Development and optimization of the prognostic markers of malignant gliomas system based on real-time PCR" and the Russian Foundation for Basic Research (grant number 18-015-00289 to TAS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.